Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer
| Autor: | Ertan, Esra, hilal oguz soydinc, Yazar, Aziz, Ustuner, Zeki, Tas, Faruk, Yasasever, Vildan |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Cancer Research Lung Neoplasms Docetaxel Vinblastine Deoxycytidine Disease-Free Survival Drug Administration Schedule 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans Aged Neoplasm Staging Aged 80 and over Smoking Vinorelbine General Medicine Middle Aged Survival Analysis Gemcitabine Treatment Outcome Oncology Matrix Metalloproteinase 9 030220 oncology & carcinogenesis Case-Control Studies Female Taxoids Cisplatin |
| Zdroj: | ResearcherID |
| ISSN: | 0300-8916 |
| Popis: | Aims and background The aim of the study was to investigate the alteration in serum matrix metalloproteinase-9 (MMP-9) levels after chemotherapy and the association between the changes in serum levels of MMP-9 and response to chemotherapy in patients with advanced stage non-small cell lung cancer. Methods and study design Twenty-eight consecutive patients with advanced non-small cell lung cancer and 24 healthy controls were enrolled in the study. The patients were treated with cisplatin-based combination chemotherapy. After two cycles, the response was evaluated. Before and after two cycles of chemotherapy, serum samples were collected from the patients. Results Prechemotherapy MMP-9 (ng/ml) levels were significantly higher in patients with advanced stage non-small cell lung cancer than in controls (7.2 ± 2.8 vs 4.5 ± 2.1, PConclusions The difference between pre- and postchemotherapy MMP-9 levels in responders was more prominent than that in nonresponders. Whether the decline in serum MMP-9 levels might be used as a marker of response to chemotherapy should be investigated in larger studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|